Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:51:10.621Z.
Calculation as of: 2026-10-06T12:51:10.621Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$14.28M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.55M
Price/FCF Ratio
25.83
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$13.34M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.30M
Price/FCF Ratio
N/A
TTM Avg
82.38
3Y Avg
82.38
5Y Avg
82.38
Market Cap
$15.91M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $14.28M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | 25.83 | 28.16 | 28.16 | 28.16 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.34M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | N/A | 82.38 | 82.38 | 82.38 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | N/A | 4.78 | 4.78 | 4.78 |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.22M | N/A | 121.92 | 75.43 | 64.77 |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | N/A | 43.53 | 55.71 | 97.87 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
